Prostamax
Synthetic Tetrapeptide | Prostate Bioregulator
Prostamax (Lys-Glu-Asp-Pro/KEDP) is a synthetic tetrapeptide bioregulator from the Khavinson peptide family that demonstrates prostate-specific tissue effects. Preclinical research shows anti-inflammatory and tissue-protective properties in chronic prostatitis models, with emerging interest in epigenetic chromatin regulation and anti-aging applications. Human clinical trial data remains limited.
Daily dose
0.5-1mg
Frequency
Once daily
Cycle length
10-20 days
Storage
2-8°C
Key benefits
Prostate tissue regulation, anti-inflammatory effects, chromatin decondensation, cellular aging modulation
How it works
Tissue-specific bioregulator that influences gene expression through heterochromatin decondensation in prostate cells and lymphocytes, potentially reactivating age-suppressed genes
Dosage protocols
Goal
Prostate Health Support
Dose
0.5-1mg daily · Once daily
Route
Subcutaneous injection
Goal
Anti-Aging Protocol
Dose
0.75mg daily · Once daily for 10-20 days
Route
Subcutaneous or oral
Goal
Oral Protocol
Dose
0.5-1mg daily · Once daily on empty stomach
Route
Oral capsule
Research indications
prostate Health
anti Aging
immune
Administration
Interactions
Safety notes
Human clinical trial data not yet published - all dosing extrapolated from preclinical models
Possible side effects include mild injection site reactions, occasional digestive discomfort, and rare headache
Contraindicated when active prostate cancer exists - theoretical concern for stimulating tumor growth
Not recommended during pregnancy, lactation, or in women generally (prostate-specific)
Quality sourcing critical - poor manufacturing can result in contamination causing adverse reactions
Consult healthcare provider before use, especially if taking prostate medications or androgen therapy
Research studies
Benign Prostatic Hyperplasia Model (2014)
Animal model | BPH parameters | Histological assessment
Study examining tetrapeptide Lys-Glu-Asp-Pro effects in benign prostatic hyperplasia model, showing favorable effects on prostate weight and histological parameters.
View study →Chronic Aseptic Prostatitis - Rat Model (2013)
Rat model | 20 μg/kg IM daily | 45 days observation | Anti-inflammatory effects
Experimental study demonstrating Prostamax reduces inflammation markers (swelling, hyperemia, lymphoid infiltration), prevents sclerotic and atrophic processes, and enhances sexual activity. Efficacy surpassed Serenoa repens and animal prostate extracts.
View study →Deheterochromatinization in Aging (2012)
Human cell cultures | Elderly subjects | Chromatin relaxation
Georgian Medical News study confirming Prostamax (KEDP) induces deheterochromatinization in chromatin from elderly subjects, potentially reversing age-related gene silencing.
View study →Lymphocyte Chromatin in Elderly Subjects (2004)
Human lymphocytes | Subjects aged 75-88 | Chromatin structure analysis
Khavinson study showing Prostamax induces ribosome gene activation, chromatin decondensation, and affects structural patterns in chromosomes 1, 9, and 16 in elderly subjects.
View study →Heterochromatin Effects - Biofizika Study (2004)
Human lymphocyte culture | In situ analysis | Epigenetic effects
Russian study by Meskhi et al. demonstrating Prostamax influences heterochromatin structure in human lymphocytes, with implications for age-related gene expression changes.
View study →